Key Takeaways
- Glaukos Corporation and RevOpsis Therapeutics have entered into an exclusive license agreement to develop and commercialize RO-104, a tri-specific biologic for the treatment for retinal disease.
- The agreement grants Glaukos exclusive rights to the RevMod platform for the discovery and development of up to four additional next-generation biologics.
- RO-104 is designed to simultaneously block VEGF-A and VEGF-C while also potently inhibiting angiopoietin-2.
Glaukos Corporation announced an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The agreement also grants Glaukos exclusive rights to RevOpsis’ proprietary RevMod platform in geographic atrophy, DME, DR, RVO, and nAMD for the discovery and development of up to four additional next-generation retinal biologic candidates.
The new therapy is designed to simultaneously block VEGF-A and VEGF-C while also potently inhibiting angiopoietin-2 (Ang-2)—pathways implicated in the progression of retinal vascular diseases. RO-104 has demonstrated superior preclinical efficacy in established animal models when compared with approved anti-VEGF therapeutics.
“This license agreement represents an important validation of our proprietary RevMod platform and our strategy of developing next-generation multi-specific therapeutics for retinal diseases," said Ramanath Bhandari, chairman and chief executive officer of RevOpsis. "Glaukos brings deep ophthalmology expertise and a strong track record of developing and commercializing innovative therapies. We believe this partnership provides an excellent opportunity to help advance our lead asset while expanding our platform into a broader portfolio of potentially transformative retinal treatments."
